



SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.

(Incorporated in the Republic of Singapore on 24 November 2011)
(Company Registration Number: 201134046D)

INTERIM UPDATE ON RECOMMENDATIONS BY STRATEGIC REVIEW COMMITTEE

Unless otherwise defined or the context otherwise requires, all capitalised terms used herein bear the same meanings as in the Announcement (as defined below).

The Board of Directors (the “**Board**”) of Singapore Institute of Advanced Medicine Holdings Ltd. (the “**Company**”, together with its subsidiaries, collectively, the “**Group**”) refers to the Company’s announcement dated 12 December 2024 (the “**Announcement**”) relating to the establishment of Strategic Review Committee (“**SRC**”).

The Board wishes to update that, following the establishment of the SRC, the SRC has reviewed and recommended, and the Board has accepted, certain proposals on initiatives primarily focused on (1) improving the utilisation of the Company’s proton beam therapy and photon radiation therapy facilities as well as its medical diagnostic equipment; and (2) the sustainability of the Company’s operations. A summary of the key initiatives is as follows:

A. Focus on Business Development

The Company intends to, amongst others, (i) focus its attention on developing its proton beam therapy and photon radiation therapy treatment businesses in Singapore and the regions where the Group operates or intends to explore operating, (ii) where permissible under laws and regulations, increase awareness on the benefits of proton beam therapy and photon radiation therapy for the healthcare practitioners and public, both locally and regionally, (iii) continue to look out for new complementary services to its present operations to generate new streams of income for its existing businesses, and (iv) engage the Group’s oncologists and other key staff in regular meetings to enhance communication and timely action on opportunities.

B. Collaborations with other Healthcare Providers

The Company intends to explore collaborations with other healthcare providers in Singapore and the Association of Southeast Asian Nations (ASEAN) region, either as a standalone service provider or as part of a hospital group. The Company aims to, through such collaborations, promote its services and increase the flow of patients to the Group’s clinics and facilities.

C. Cost Saving Measures

The Company also intends to reduce its operational costs and expenses by reaching out to various business contacts and/or service providers of the Group for, amongst others, reduction of fees and charges for the provision of services, and deferment of payment of all or part of such fees and charges.

The Company will update shareholders as and when there are material developments.

BY ORDER OF THE BOARD

Dr Djeng Shih Kien
Executive Director and Chief Executive Officer
28 February 2025

Singapore Institute of Advanced Medicine Holdings Ltd. (the "**Company**") was listed on Catalist of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") on 16 February 2024. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**").

This announcement has been reviewed by the Sponsor. It has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms. Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.